[Skip to Navigation]
Views 533
Citations 0
November 7, 2019

SETD2 Mutation in an Aggressive Optic Nerve Glioma

Author Affiliations
  • 1Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland
  • 2Ophthalmic Plastic and Reconstructive Surgery, Orbital Surgery Division, Department of Ophthalmology, New York Presbyterian Hospital, Columbia University Irving Medical Center, New York
  • 3Division of Pediatric Hematology/Oncology/Stem Cell Transplant, Department of Pediatrics, Columbia University Irving Medical Center, New York, New York
  • 4Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York
JAMA Ophthalmol. 2020;138(1):102-104. doi:10.1001/jamaophthalmol.2019.4511

Optic nerve gliomas (ONGs) in children are uniformly low-grade gliomas that frequently cause vision loss. Optic nerve gliomas in adults are reported to be more clinically aggressive with frequent transformation into high-grade gliomas. We report a child with sporadic ONG and an aggressive clinical course. Tumor molecular characterization identified KIAA1549-BRAF fusion but also set domain-containing protein 2 (SETD2; OMIM, 612778) mutation, previously reported only, to our knowledge, in high-grade gliomas and non–central nervous system cancers.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words